Drug Safety expert proficient with the latest and upcoming trends in drug safety required for long term advanced safety analytics advisory.  An RNA based platform with multiple indications, applying advanced safety analytics to support the entire portfolio, as opposed to only one indication at a time, is a core strategy for the drug sponsor.  Expert consulting required to help sponsor pilot the Aggregate Safety Assessment Planning Process, use of interactive safety graphics, tie in to structured risk-benefit reporting and other advanced safety analytics needs.  It is anticipated that this consultancy will require widely variable (not full time) hours over at least 2 years to ensure adoption success.